Alliance with Roche

Launched Xeloda®, an anti-cancer agent (Mar.)

Launched Pegasys®, peginterferon alfa-2a(genetical recombination) (Dec.)

Established Chugai Clinical Research Center Co., Ltd. (Sep.)

Transferred the OTC (over-the-counter medicines) business to Lion Corporation Transferred the insecticide manufacturing business of Eiko Kasei Co., Ltd. to Lion Packaging Co., Ltd. (Dec.)

Closed the Tsukuba Research Laboratory (Mar.)

Established Forerunner Pharma Research Co., Ltd. by Chugai Pharmaceutical Co., Ltd., Mitsui & Co., Ltd., and the Central Institute for Experimental Animals (Apr.)

Transferred the Kagamiishi Plant and all stocks of Tohoku Chugai Pharmaceutical Co., Ltd. to Nipro Corporation (Jun.)

Assigned specialist MRs in oncology and renal area (Jul.)

Chugai Pharma Manufacturing Co., Ltd. succeeded to the business of manufacturing pharmaceutical products conducted at Chugai's Ukima Plant, Fujieda Plant, Utsunomiya Plant and Kamakura Plant as the result of a company split (May)

Launched Copegus®, an antiviral agent (Mar.)

Launched Avastin®, an anti-cancer agent (Jun.)

Launched Tarceva®, an anti-cancer agent (Dec.)

Approval of Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, for additional indication in Japan (Apr.)

Approval of Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, in the EU (Jan.)

Approval of Actemra®, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody, in the United States (Jan.)

Closed the Kamakura plant of Chugai Pharma Manufacturing Co., Ltd. (Jun.)

Established Clinical Research Center of C&C Research Laboratorie (Feb.)

Launched Edirol®, an active vitamin D3 derivative (Apr.)

Launched Mircera®, a long-acting erythropoiesis stimulating agent (Jul.)

Established Chugai Pharmabody Research Pte. Ltd. in Singapore (Jan.)

Tatsuro Kosaka appointed as Representative Director and President (Mar.)

Launched Pulmozyme®, a Recombinant Human Deoxyribonuclease I (rhDNase) (Jun.)

Succeeded in establishing stable cell lines of cancer stem cell for the First Time (Oct.)

Launched Bonviva®, an ibandronate sodium hydrate, a bisphosphonate antiresorptive agent for Osteoporosis (Aug.)

Launched Perjeta®, an anti-cancer agent (Sep.)

Established Chugai Pharma China Co., Ltd. (Mar.)

Launched Kadcyla®, an anti-cancer agent (Apr.)

Amendment of business arrangements regarding the conditions for out-licensing Chugai products based on the strategic alliance between Chugai and Roche (Aug.)

Launched Alecensa®, an anti-cancer agent (Sep.)

Launched Zelboraf®, an anti-cancer agent(Feb.)

Establishment of Translational Clinical Research Division (Apr.)

Integration and Reorganization of Chugai’s subsidiaries in Europe, China and Taiwan (Jul.)

Approval of Alecensa®, an anti-cancer agent, in the United States (Dec.)

Announcement on the Purchase of Land for Business in Yokohama-shi, Kanagawa Prefecture (Mar.)

Comprehensive Collaboration Agreement between Osaka University and Chugai (May)

Approval of Alecensa®, an anti-cancer agent, in Europe (Feb.)

Approval of HEMLIBRA®, anti-coagulation factor IXa/X humanized bispecific monoclonal antibody / coagulation factor VIII substitute, in the United States (Nov.)

Launched ALAGLIO®, a photodynamic diagnostic agent (Dec.)

Approval of HEMLIBRA®, anti-coagulation factor IXa/X humanized bispecific monoclonal antibody / coagulation factor VIII substitute, in Europe (Feb.)

Tatsuro Kosaka appointed as CEO (Mar.)

Launched TECENTRIQ®, an anti-cancer agent (Apr.)

Launched HEMLIBRA®, anti-coagulation factor IXa/X humanized bispecific monoclonal antibody / coagulation factor VIII substitute (May)

Launched Gazyva®, an anti-CD20 monoclonal antibody (Aug.)

Execution of Asset Transfer of 13 Long-Term Products to Taiyo Pharma (Jan.)

Launched FoundationOne® CDx Cancer Genomic Profile, a diagnostic program (Jun.)

Launched Rozlytrek®, an anti-cancer agent (Sep.)

Establishment of Division (Oct.)